Other studies have confirmed the frequent overexpression of CD123 in FLT3-ITD-mutated AMLs and in NPM1-mutated AMLs; in particular, Rollins-Raval and coworkers reported a CD123 overexpression in 83% of FLT3-ITD-mutated AMLs and in 62% of NPM1-mutated AMLs [20]; Brass and coworkers in a large screening on more than 200 AML samples confirmed that the highest CD123 expression was observed in FLT3-ITD and NPM1-mutated AMLs [21]. This evidence concerns the gene FLT3 and acute myeloid leukemia.